Alam Asim, Juurlink David N
Department of Anesthesia, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Trauma, Emergency and Critical Care Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Can J Anaesth. 2016 Jan;63(1):61-8. doi: 10.1007/s12630-015-0520-y. Epub 2015 Oct 27.
The objectives for preparing this article were to review the historical context and epidemiology surrounding the North American prescription opioid crisis, to summarize the evidence regarding the benefits and harms of long-term opioid therapy for non-cancer pain, and to outline ways in which anesthesiologists may help ameliorate the problem.
We searched PubMed, Google Scholar, and EMBASE™ for relevant articles using various search terms, including pain, opioid epidemic, history of opioid use, perioperative care, and addiction. Related citations were further explored and searched depending on the specific subtopic of interest.
In the 1980s and early 1990s, opioids were infrequently used for the treatment of chronic pain. Thereafter, however, physicians were gradually inculcated with the message that long-term opioid therapy was a safe and effective treatment option for patients with chronic non-cancer pain. Pharmaceutical companies supported this growing movement and employed aggressive and sometimes misleading marketing strategies for new opioid formulations. As a result, the practice of prescribing opioids flourished in the late 1990s. The surge in prescribing opioids was accompanied by a marked increase in opioid-related morbidity and mortality. This change in practice transpired despite the absence of randomized trials showing clinically significant benefit from the long-term use of opioids. Subsequently, however, a large and growing body of evidence has emerged quantifying the harms associated with long-term opioid therapy. Anesthesiologists widely prescribe opioids for acute and chronic pain; yet, as a group, they may be largely unaware of the current state of this growing epidemic and what role they can play to rectify this problem.
Anesthesiologists are well positioned to take a leadership role in the management of postoperative discharge opioid therapy in an effort to curb the overutilization of opioids. Furthermore, anesthesiologists who regularly prescribe opioids for chronic pain patients should appreciate the limited evidence base for this practice and communicate the risks of opioid therapy to their patients.
撰写本文的目的是回顾围绕北美处方阿片类药物危机的历史背景和流行病学情况,总结长期阿片类药物治疗非癌性疼痛的益处和危害的相关证据,并概述麻醉医生可帮助缓解该问题的方法。
我们使用各种搜索词在PubMed、谷歌学术和EMBASE™中搜索相关文章,包括疼痛、阿片类药物流行、阿片类药物使用史、围手术期护理和成瘾。根据感兴趣的具体子主题进一步探索和搜索相关引用文献。
在20世纪80年代和90年代初,阿片类药物很少用于治疗慢性疼痛。然而,此后,医生们逐渐被灌输这样的观念,即长期阿片类药物治疗是慢性非癌性疼痛患者的一种安全有效的治疗选择。制药公司支持这一不断发展的趋势,并对新的阿片类药物制剂采用积极且有时具有误导性的营销策略。结果,在20世纪90年代后期,开具阿片类药物的做法盛行起来。阿片类药物处方量的激增伴随着阿片类药物相关发病率和死亡率的显著增加。尽管缺乏随机试验表明长期使用阿片类药物有临床显著益处,但这种做法仍发生了改变。然而,随后出现了大量且不断增加的证据,量化了与长期阿片类药物治疗相关的危害。麻醉医生广泛为急性和慢性疼痛开具阿片类药物;然而,作为一个群体,他们可能很大程度上没有意识到这一日益严重的流行病的现状以及他们在纠正这一问题中可以发挥的作用。
麻醉医生有能力在术后出院阿片类药物治疗管理中发挥领导作用,以遏制阿片类药物的过度使用。此外,定期为慢性疼痛患者开具阿片类药物的麻醉医生应认识到这种做法的证据基础有限,并向患者传达阿片类药物治疗的风险。